Literature DB >> 28272702

Clinical significance of serum MCP-1 and VE-cadherin levels in patients with acute cerebral infarction.

X He1, D-R Li, C Cui, L-J Wen.   

Abstract

OBJECTIVE: Vascular injuries have been proposed to play a role in cerebral infarction (CI)-induced brain damage. In this study, the expressions of monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial-cadherin (VE-Cadherin) in patients with acute stroke was examined, and the clinical significance was analyzed. PATIENTS AND METHODS: 102 patients with acute CI between February 2012 and 2015 were recruited in this study. Among these patients, 43 patients presented with progressive cerebral infarction (PCI) while 59 patients presented with non-progressive cerebral infarction (NPCI). The carotid intima-media thickness (IMT) of all patients was measured by ultrasound as a marker of end-organ damage. Our results showed that 26 patients had normal IMT, 19 patients had a thickening carotid wall and 57 patients presented with a carotid plaque. In our study, 52 healthy volunteers screened by medical checkups in our hospital during the same period were taken as control group. The MCP-1 and VE-cadherin expressions in each group were detected and analyzed.
RESULTS: Compared to the control group, the patients in the experimental group had significantly elevated serum MCP-1 and VE-cadherin levels (p < 0.05). Compared to the NPCI patients, the serum MCP-1 and VE-cadherin levels of the patients with PCI were significantly increased, and the rate of carotid plaque was increased as well, especially in the mixed echo and low echo plaques. Then compared with the patients with normal IMT and thickening carotid wall, the patients with carotid plaques had notably increased MCP-1 and VE-cadherin levels.
CONCLUSIONS: For patients with PCI, the serum MCP-1 and VE-cadherin levels were significantly increased. Moreover, serum MCP-1 and VE-cadherin levels were correlated with atherosclerosis and the stability of atherosclerotic plaques in patients with cerebral infarction.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28272702

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Expression and significance of S-100β, CysC and NF-κB in patients with acute cerebral infarction.

Authors:  Zaili Li; Zaie Xin
Journal:  Exp Ther Med       Date:  2020-12-16       Impact factor: 2.447

Review 2.  Efficacy of Danshen Class Injection in the Treatment of Acute Cerebral Infarction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Shi Liu; Kaihuan Wang; Xiaojiao Duan; Jiarui Wu; Dan Zhang; Xinkui Liu; Yi Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-03       Impact factor: 2.629

3.  Effect of Danhong injection on neurological recovery and adverse events in patients with acute ischemic stroke: A protocol for a randomized, double-blind, placebo-controlled clinical study.

Authors:  Junfeng Gao; Xiangzhong Shao; YiXiang Guan; Juxiang Mei
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

Review 4.  The Role of CCL2/CCR2 Axis in Cerebral Ischemia-Reperfusion Injury and Treatment: From Animal Experiments to Clinical Trials.

Authors:  Huixia Geng; Luna Chen; Jing Tang; Yi'ang Chen; Lai Wang
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

5.  Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction.

Authors:  Lilin Gao; Shaojie Zhang; Xuewen Wo; Xiangpeng Shen; Qiangyuan Tian; Guoqing Wang
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 1.088

6.  Association of DNA Methylation Patterns in 7 Novel Genes With Ischemic Stroke in the Northern Chinese Population.

Authors:  Hongwei Sun; Jia Xu; Bifeng Hu; Yue Liu; Yun Zhai; Yanyan Sun; Hongwei Sun; Fang Li; Jiamin Wang; Anqi Feng; Ying Tang; Jingbo Zhao
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.